Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

Gilead Sciences posted better-than-expected top- and bottom-line results in the latest quarter, which the company credited to its virology and oncology segments. The biopharmaceutical company ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...

Gilead Sciences' had an incredibly strong 2023. The company finally started to show the results of its acquisitions, with oncology sales increasing dramatically YoY.

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

For Gilead Sciences to profit from the expanded label, we also must look at COVID-19 numbers. While the pandemic is no longer dominating the main headlines, COVID-19 is not gone.

Gilead Sciences (GILD -0.93%) stock has been a standout among biotech companies over the past year, with its shares up more than 36%. Over the past decade, its shares delivered a total return of a ...

Gilead Sciences Inc. GILD -2.13% will pay $4.9 billion to buy Forty Seven Inc., a five-year-old biotech company with a promising blood-cancer medicine that could be on the market within two years ...